AKBA - Akebia Therapeutics, Inc.
After hours:
| Previous close | 1.2000 |
| Open | 1.2200 |
| Bid | 1.2700 x 3200 |
| Ask | 1.2700 x 1800 |
| Day's range | 1.2100 - 1.3200 |
| 52-week range | 0.2410 - 1.6300 |
| Volume | |
| Avg. volume | 1,720,714 |
| Market cap | 237.988M |
| Beta (5Y monthly) | 0.73 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3300 |
| Earnings date | 02 Aug 2023 - 07 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.00 |
ZacksAll You Need to Know About Akebia Therapeutics (AKBA) Rating Upgrade to Buy
Akebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ZacksAre Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?
Here is how Akebia Therapeutics (AKBA) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
Motley FoolWhy Shares of Akebia Therapeutics Were Up Tuesday
Shares of Akebia Therapeutics (NASDAQ: AKBA) were up more than 10% Tuesday after rising to as high as 13.1% in early trading. The biopharmaceutical company, which specializes in therapies to fight kidney disease, has seen its shares climb more than 168% so far this year. On Monday, the company announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) had granted marketing approval for Vafseo (vadadustat) to treat anemia connected with chronic kidney disease in adults on maintenance dialysis.
ZacksIs Novartis (NVS) Stock Outpacing Its Medical Peers This Year?
Here is how Novartis (NVS) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
ZacksAkebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 6.67% and 14.05%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksWill CTI BioPharma (CTIC) Report Negative Earnings Next Week? What You Should Know
CTI BioPharma (CTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksWill Akebia Therapeutics (AKBA) Report Negative Q1 Earnings? What You Should Know
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Simply Wall St.Benign Growth For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Underpins Its Share Price
With a price-to-sales (or "P/S") ratio of 0.4x Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) may be sending very bullish...
ZacksAkebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 71.43% and 14.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Akebia Therapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags
Akebia Therapeutics ( NASDAQ:AKBA ) Third Quarter 2022 Results Key Financial Results Revenue: US$49.0m (flat on 3Q...
ZacksAkebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -86.67% and 3.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ZacksAkebia Therapeutics (AKBA) Surpasses Q2 Earnings and Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 174.19% and 158.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
